Literature DB >> 26139079

Cytopathologic features of epithelioid inflammatory myofibroblastic sarcoma with correlation of histopathology, immunohistochemistry, and molecular cytogenetic analysis.

Jen-Chieh Lee1, Jiann-Ming Wu2, Jau-Yu Liau1, Hsuan-Ying Huang3, Cheng-Yu Lo4, I-Shiow Jan5, Jason L Hornick6, Xiaohua Qian6.   

Abstract

BACKGROUND: Epithelioid inflammatory myofibroblastic sarcoma (E-IMS) is a recently established rare variant of inflammatory myofibroblastic tumor. It is characterized by a distinctive constellation of clinical, pathological, and molecular features, including a nearly exclusive intraabdominal location, strong male predilection, aggressive clinical course, predominance of epithelioid tumor cells, and Ran-binding protein 2 (RANBP2)-anaplastic lymphoma kinase (ALK) fusion in the majority of cases. To the authors' knowledge, the cytologic features of E-IMS have not been described to date.
METHODS: Cases of E-IMS that had corresponding cytology were searched. Six cytology samples (1 fine-needle aspiration sample, 2 imprint samples, and 3 effusion fluids) containing tumor cells were identified in 5 patients with E-IMS.
RESULTS: The cytomorphology included large monotonous epithelioid cells arranged in loose aggregates or singly, with admixed myxoid stroma, and an inflammatory background rich in neutrophils. The tumor cells had a large, round, eccentric nucleus with vesicular chromatin, prominent nucleoli, and moderate amounts of pale cytoplasm. Delicate thin-walled branching vessels traversing tumor aggregates was a prominent feature in a fine-needle aspiration sample. Immunohistochemically, ALK was positive in all 5 tumors, with a nuclear membranous staining pattern noted in 3 cases and a cytoplasmic pattern observed in the other 2 cases. ALK rearrangement was confirmed in all 5 tumors by molecular genetic studies.
CONCLUSIONS: The cytologic features of E-IMS recapitulate its histologic characteristics. E-IMS merits inclusion in the differential diagnosis of any intraabdominal, large epithelioid cell neoplasm. Confirmation of ALK rearrangement is advisable because patients may benefit from targeted therapies.
© 2015 American Cancer Society.

Entities:  

Keywords:  RANBP2 (Ran-binding protein 2)-ALK; anaplastic lymphoma kinase (ALK); cytology; epithelioid; fine-needle aspiration; inflammatory myofibroblastic tumor; sarcoma

Mesh:

Substances:

Year:  2015        PMID: 26139079     DOI: 10.1002/cncy.21558

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  3 in total

Review 1.  Epithelioid inflammatory myofibroblastic sarcoma treated with ALK inhibitor: a case report and review of literature.

Authors:  Qiuyu Liu; Yunzhen Kan; Yuewu Zhao; Hui He; Lingfei Kong
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

2.  Identification of EML4-ALK as an alternative fusion gene in epithelioid inflammatory myofibroblastic sarcoma.

Authors:  Quan Jiang; Han-Xing Tong; Ying-Yong Hou; Yong Zhang; Jing-Lei Li; Yu-Hong Zhou; Jing Xu; Jiong-Yuan Wang; Wei-Qi Lu
Journal:  Orphanet J Rare Dis       Date:  2017-05-23       Impact factor: 4.123

Review 3.  Inflammatory Myofibroblastic Tumour: State of the Art.

Authors:  Louis Gros; Angelo Paolo Dei Tos; Robin L Jones; Antonia Digklia
Journal:  Cancers (Basel)       Date:  2022-07-27       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.